Jennifer K. Litton, MD

The University of Texas MD Anderson Cancer Center, Houston, TX

Authored Items

Efficacy/Safety of Talazoparib or Physician’s Choice of Therapy in US Patients with HER2-Negative Germline BRCA1/2-Mutated Locally Advanced/Metastatic Breast Cancer (EMBRACA)
Sami Diab, MD, Hope S. Rugo, MD, Lida A. Mina, MD, Shannon Puhalla, MD, Reshma Mahtani, DO, N. Lynn Henry, MD, PhD, Neelima Denduluri, MD, Denise Yardley, MD, Yao Wang, MD, Lillian Shahied Arruda, PhD, Iulia C. Tudor, PhD, Eric Gauthier, PharmD, PhD, Akos Czibere, MD, PhD, Jennifer K. Litton, MD, Sara A. Hurvitz, MD
AONN+ Conference Abstracts, Clinical Research
November 2019 Vol 10, No 11
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer.
Read More
Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?